Trisalus Life Sciences Inc 's ability to collect its outstanding accounts receivable from its corporate clients, has improved in the first quarter 2026 to a ratio of 7.91, above the company average. This is a clear sign of healthy business climate in the Medical Equipment & Supplies industry and improving liquidity at their respective customers, during the first quarter 2026. Average receivable collection period, for the Trisalus Life Sciences Inc in Mar 31 2026 quarter, has decreased to 46 days, compared to 47 days, in the Dec 31 2025 quarter.

If we take a look into Healthcare sector 117 other companies have achieved higher receivables turnover ratio. While total ranking has deteriorated relative to the period ending Mar 31 2026 from 435 to 972.

What is Receivable Turnover Ratio?
What is Trisalus Life Sciences Inc Selling?

What is Receivable Turnover Ratio?

Select the Comparisons :

None ▼

Select the Ratio:

Accounts Receivables Turnover▼

None ▼

Accounts Receivables Turnover▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

TLSI Receivables Turnover Ratio	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter	(Mar 31 2025) I. Quarter
Y / Y Receivable Change	-4.36 %	28.92 %	1.79 %	18.38 %	27.5 %
Y / Y Revenue Change	-0.03 %	76.95 %	45.13 %	41.38 %	34.3 %
Receivable Turnover Ratio (TTM)	7.91	7.83	7.18	6.58	6.26
TLSI's Total Ranking	# 972	# 435	# 685	# 1772	# 2026
Accounts Receivable average collection period days	46	47	51	55	58
Seq. Receivable Change	-20.48 %	31.16 %	-10.25 %	2.16 %	7.19 %
Seq. Revenue Change	-39.98 %	35.49 %	2.39 %	20.05 %	6.25 %

Receivable Turnover Company Ranking
Within:	No.
Medical Equipment & Supplies Industry	# 53
Healthcare Sector	# 118
Overall Market	# 972

Receivable Turnover Ratio Statistics
High	Average	Low
1.31	1.16	0.96
(Sep 30 2024)		(Mar 31 2026)

News about Trisalus Life Sciences Inc Receivables Turnover Ratios

TriSalus Reports Strong Q2 2024 Growth and Strategic Developments in Cancer Treatment

TriSalus Reports Q2 2024 Financial Results and Business Update In a recent announcement, TriSalus Life Sciences, a leader in the development of innovative therapies for solid tumors, shared its financial results for the second quarter of 2024 and provided insight into its strategic initiatives. The report highlighted both the robust financial performance of the company and its ongoing commitment to advancing treatment options for patients facing the challenges of cancer. TriSalus reported a revenue increase of 35% year-over-year, driven primarily by the successful launch of its proprietary immunotherapy treatments. This growth underscores the healthy demand for the company’s offerings and reflects TriSalus’s market positioning as a critical player in the oncology space. The company s CEO, Tom O’Brien, noted that this spike in revenue signifies not only the successful execution of their business strategy but also the positive reception of their leading product, which has shown promising results in clinical trials.Additionally, the company reported a net loss of $5 million for the quarter, which is consistent with its investment strategy aimed at scaling operations and expanding research and development efforts. According to O’Brien, these investments are essential for expanding TriSalus s pipeline, which currently includes several late-stage clinical trials focusing on a range of solid tumors.

TLSI Company Profile • Back to TLSI Efficiency Comparisons • Compare TLSI Receivables Turnover Ratio to its Competitors

Financial Statements
Trisalus Life Sciences Inc 's Accounts Receivable	$ 5 Millions	Visit TLSI's Balance sheet
Trisalus Life Sciences Inc 's Sales TTM	$ 44 Millions	Visit TLSI's Income Statement
Sources of TLSI's Revenues		Visit TLSI's Sales by Geography

Other Accounts Receivable Turnover Ratios
Medical Equipment & Supplies Industry Accounts Receivable Turnover Trends and Statistics
Healthcare Sector Accounts Receivable Turnover Statistics
Accounts Receivables Turnover Trends for overall market
TLSI's Receivable Turnover Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and total Market
Highest Ranking Accounts Receivables Turnover
Lowest Ranking Accounts Receivables Turnover

You may also want to know
TLSI's Growth Rates	TLSI's Roa	TLSI's Inventory Turnover Ratio	TLSI's Dividend Comparisons
TLSI's Profitability Ratios	TLSI's Roi	TLSI's Asset Turnover Ratio	TLSI's Dividend Growth
TLSI's Valuation Ratios	TLSI's Roe	TLSI's Financial Strength Ratios	TLSI's Dividend Payout Ratio

Companies with similar Receivables Turnover Ratio for the quarter ending Mar 31 2026, within Healthcare Sector	Receivable Turnover Ratio	Revenues for 12 Months ending Mar 31 2026	Receivable at quarter ending Mar 31 2026
Cytomx Therapeutics Inc	23.09	$ 35.542 Millions	$ 1.539 Millions
Siga Technologies Inc	22.41	$ 93.777 Millions	$ 4.186 Millions
Lipocine Inc	22.09	$ 2.002 Millions	$ 0.091 Millions
Ataibeckley Inc	21.56	$ 3.488 Millions	$ 0.162 Millions
Fonar Corporation	21.15	$ 105.338 Millions	$ 4.981 Millions
Neuraxis Inc	20.94	$ 4.282 Millions	$ 0.204 Millions
Vystar Corporation	20.58	$ 0.048 Millions	$ 0.002 Millions
Lifemd Inc	19.91	$ 177.869 Millions	$ 8.934 Millions
Longeveron Inc	19.07	$ 1.216 Millions	$ 0.064 Millions
Sonida Senior Living Inc	18.82	$ 411.850 Millions	$ 21.878 Millions
Nutriband Inc	16.79	$ 1.803 Millions	$ 0.107 Millions
Bioadaptives Inc	16.64	$ 0.024 Millions	$ 0.001 Millions
Premier Air Charter Holdings Inc	16.33	$ 33.205 Millions	$ 2.033 Millions
Bioage Labs Inc	15.90	$ 10.316 Millions	$ 0.649 Millions
Escalon Medical Corp	15.15	$ 11.445 Millions	$ 0.756 Millions
Nurix Therapeutics Inc	15.11	$ 71.779 Millions	$ 4.750 Millions
Rosecliff Acquisition Corp I	15.05	$ 23.433 Millions	$ 1.557 Millions
Lexicon Pharmaceuticals Inc	14.91	$ 69.643 Millions	$ 4.670 Millions
Qhslab Inc	14.80	$ 2.775 Millions	$ 0.188 Millions
Nexgel Inc	14.19	$ 10.382 Millions	$ 0.732 Millions
Sutro Biopharma Inc	14.04	$ 99.608 Millions	$ 7.095 Millions
Precipio inc	13.93	$ 25.831 Millions	$ 1.854 Millions
China Pharma Holdings Inc	13.86	$ 3.992 Millions	$ 0.288 Millions
Talkspace Inc	13.67	$ 239.269 Millions	$ 17.501 Millions
Marpai Inc	13.59	$ 17.125 Millions	$ 1.261 Millions
Amneal Pharmaceuticals Inc	13.56	$ 3,045.530 Millions	$ 224.634 Millions
Corcept Therapeutics Inc	13.20	$ 769.096 Millions	$ 58.264 Millions
Xoma Royalty Corporation	13.05	$ 48.555 Millions	$ 3.720 Millions
Mannkind Corporation	13.00	$ 360.783 Millions	$ 27.757 Millions
Lifestance Health Group Inc	12.74	$ 1,494.791 Millions	$ 117.296 Millions

Date modified: 2026-08-29T17:43:44+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.